Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 10'th Dec 2025
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
04:00pm, Monday, 08'th Dec 2025
Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived
01:01pm, Monday, 08'th Dec 2025
Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's
Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?
11:16am, Tuesday, 02'nd Dec 2025
Investors need to pay close attention to ARQT stock based on the movements in the options market lately.
Why Shares in Arcutis Biotherapeutics Surged Again This Week
03:47am, Friday, 21'st Nov 2025
Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance for Zoryve.
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
10:16am, Thursday, 20'th Nov 2025
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Campbell & CO Investment Adviser LLC Lowers Holdings in Arcutis Biotherapeutics, Inc. $ARQT
03:53am, Tuesday, 18'th Nov 2025
Campbell and CO Investment Adviser LLC trimmed its stake in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 78.5% during the undefined quarter, according to its most recent disclosure with the Securit
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
10:36am, Monday, 17'th Nov 2025
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 20-day moving average, suggest
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
02:31pm, Sunday, 16'th Nov 2025
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with
CrowdStrike Leads Five Stocks To Watch Near Buy Points
08:00am, Saturday, 15'th Nov 2025
CrowdStrike is the lone technology company on the list after AI plays' bruising last week. But all five stocks to watch are near buy points.
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approv
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 07'th Nov 2025
WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade
10:55am, Wednesday, 05'th Nov 2025
The consensus price target hints at a 26.5% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis
